{"id":688988,"date":"2022-09-26T17:04:31","date_gmt":"2022-09-26T21:04:31","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/hepion-pharmaceuticals-to-participate-in-the-cantor-oncology-hematology-hemeonc-conference\/"},"modified":"2022-09-26T17:04:31","modified_gmt":"2022-09-26T21:04:31","slug":"hepion-pharmaceuticals-to-participate-in-the-cantor-oncology-hematology-hemeonc-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/hepion-pharmaceuticals-to-participate-in-the-cantor-oncology-hematology-hemeonc-conference\/","title":{"rendered":"Hepion Pharmaceuticals to Participate in the Cantor Oncology, Hematology &amp; HemeOnc Conference"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">EDISON, N.J., Sept.  26, 2022  (GLOBE NEWSWIRE) &#8212; Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (\u201cAI\u201d)-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis (\u201cNASH\u201d), hepatocellular carcinoma (\u201cHCC\u201d), and other chronic liver diseases, today announced that its Chief Medical Officer, Todd Hobbs, MD, will participate in the \u201cNovel Targets in Oncology: Risk vs. Reward\u201d panel at the Cantor Oncology, Hematology &amp; HemeOnc Conference on Wednesday, September 28, 2022 at 9:00 a.m. Eastern Time at the New York Palace Hotel.<\/p>\n<p align=\"justify\">During the panel alongside other industry peers, Dr. Hobbs will focus his discussion on Hepion\u2019s upcoming Phase 2 clinical trial of rencofilstat in the treatment of HCC. Due to the format of the event, no webcast will be available.<\/p>\n<p align=\"justify\">\n        <strong>About Hepion Pharmaceuticals <\/strong>\n      <\/p>\n<p align=\"justify\">The Company&#8217;s lead drug candidate, rencofilstat, is a potent inhibitor of cyclophilins, which are involved in many disease processes. Rencofilstat is currently in clinical-phase development for the treatment of NASH, with the potential to play an important role in the overall treatment of liver disease &#8211; from triggering events through to end-stage disease. Rencofilstat has been shown to reduce liver fibrosis and hepatocellular carcinoma tumor burden in experimental models of NASH, and has demonstrated antiviral activities towards HBV, HCV, and HDV through several mechanisms, in nonclinical studies. In November 2021, the U.S. Food and Drug Administration (\u201cFDA\u201d) granted Fast Track designation for rencofilstat for the treatment of NASH. That was followed in June 2022 by the FDA\u2019s granting of Orphan Drug designation to rencofilstat for the treatment of HCC.<\/p>\n<p align=\"justify\">Hepion has created a proprietary AI platform, called AI-POWR\u2122, which stands for <strong>A<\/strong>rtificial Intelligence &#8211; <strong>P<\/strong>recision Medicine; <strong>O<\/strong>mics (including genomics, proteomics, metabolomics, transcriptomics, and lipidomics); <strong>W<\/strong>orld database access; and <strong>R<\/strong>esponse and clinical outcomes. Hepion intends to use AI-POWR\u2122 to help identify which NASH patients will best respond to rencofilstat, potentially shortening development timelines and increasing the delta between placebo and treatment groups. In addition to using AI-POWR\u2122 to drive its ongoing NASH clinical development program, Hepion intends to use the platform to identify additional potential indications for rencofilstat to expand the company&#8217;s footprint in the cyclophilin inhibition therapeutic space.<\/p>\n<p align=\"justify\">For further information, please contact:<\/p>\n<p align=\"justify\">Stephen Kilmer<br \/>Hepion Pharmaceuticals Investor Relations<br \/>Direct: (646) 274-3580<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=_Ll-TItBIhl0t6VODqVRDndVjLmflVt8vsXevxDYyY6y6RDcsj5w3Y7gcWhQKUPYlK5GgndT5b1Lvka_Zvi4QEyvgkQKhMC2uPFPW1rNn-w=\" rel=\"nofollow noopener\" target=\"_blank\">skilmer@hepionpharma.com<\/a>\u00a0\u00a0<\/p>\n<p \/>\n      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1MzU1NiM1MTcyNTY2IzIwODI1NzU=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/NzIwMDNhNDQtYTlkNS00ZWU2LWIwZmEtZTVmZTU3ZDE3ZjdhLTEwOTQxNDY=\/tiny\/Hepion-Pharmaceuticals-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>EDISON, N.J., Sept. 26, 2022 (GLOBE NEWSWIRE) &#8212; Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (\u201cAI\u201d)-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis (\u201cNASH\u201d), hepatocellular carcinoma (\u201cHCC\u201d), and other chronic liver diseases, today announced that its Chief Medical Officer, Todd Hobbs, MD, will participate in the \u201cNovel Targets in Oncology: Risk vs. Reward\u201d panel at the Cantor Oncology, Hematology &amp; HemeOnc Conference on Wednesday, September 28, 2022 at 9:00 a.m. Eastern Time at the New York Palace Hotel. During the panel alongside other industry peers, Dr. Hobbs will focus his discussion on Hepion\u2019s upcoming Phase 2 clinical trial of rencofilstat in the treatment of HCC. Due to the format of the event, &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/hepion-pharmaceuticals-to-participate-in-the-cantor-oncology-hematology-hemeonc-conference\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Hepion Pharmaceuticals to Participate in the Cantor Oncology, Hematology &amp; HemeOnc Conference&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-688988","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.1 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Hepion Pharmaceuticals to Participate in the Cantor Oncology, Hematology &amp; HemeOnc Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/hepion-pharmaceuticals-to-participate-in-the-cantor-oncology-hematology-hemeonc-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Hepion Pharmaceuticals to Participate in the Cantor Oncology, Hematology &amp; HemeOnc Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"EDISON, N.J., Sept. 26, 2022 (GLOBE NEWSWIRE) &#8212; Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (\u201cAI\u201d)-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis (\u201cNASH\u201d), hepatocellular carcinoma (\u201cHCC\u201d), and other chronic liver diseases, today announced that its Chief Medical Officer, Todd Hobbs, MD, will participate in the \u201cNovel Targets in Oncology: Risk vs. Reward\u201d panel at the Cantor Oncology, Hematology &amp; HemeOnc Conference on Wednesday, September 28, 2022 at 9:00 a.m. Eastern Time at the New York Palace Hotel. During the panel alongside other industry peers, Dr. Hobbs will focus his discussion on Hepion\u2019s upcoming Phase 2 clinical trial of rencofilstat in the treatment of HCC. Due to the format of the event, &hellip; Continue reading &quot;Hepion Pharmaceuticals to Participate in the Cantor Oncology, Hematology &amp; HemeOnc Conference&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/hepion-pharmaceuticals-to-participate-in-the-cantor-oncology-hematology-hemeonc-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2022-09-26T21:04:31+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1MzU1NiM1MTcyNTY2IzIwODI1NzU=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hepion-pharmaceuticals-to-participate-in-the-cantor-oncology-hematology-hemeonc-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hepion-pharmaceuticals-to-participate-in-the-cantor-oncology-hematology-hemeonc-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Hepion Pharmaceuticals to Participate in the Cantor Oncology, Hematology &amp; HemeOnc Conference\",\"datePublished\":\"2022-09-26T21:04:31+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hepion-pharmaceuticals-to-participate-in-the-cantor-oncology-hematology-hemeonc-conference\\\/\"},\"wordCount\":381,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hepion-pharmaceuticals-to-participate-in-the-cantor-oncology-hematology-hemeonc-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODY1MzU1NiM1MTcyNTY2IzIwODI1NzU=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hepion-pharmaceuticals-to-participate-in-the-cantor-oncology-hematology-hemeonc-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hepion-pharmaceuticals-to-participate-in-the-cantor-oncology-hematology-hemeonc-conference\\\/\",\"name\":\"Hepion Pharmaceuticals to Participate in the Cantor Oncology, Hematology &amp; HemeOnc Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hepion-pharmaceuticals-to-participate-in-the-cantor-oncology-hematology-hemeonc-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hepion-pharmaceuticals-to-participate-in-the-cantor-oncology-hematology-hemeonc-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODY1MzU1NiM1MTcyNTY2IzIwODI1NzU=\",\"datePublished\":\"2022-09-26T21:04:31+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hepion-pharmaceuticals-to-participate-in-the-cantor-oncology-hematology-hemeonc-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hepion-pharmaceuticals-to-participate-in-the-cantor-oncology-hematology-hemeonc-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hepion-pharmaceuticals-to-participate-in-the-cantor-oncology-hematology-hemeonc-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODY1MzU1NiM1MTcyNTY2IzIwODI1NzU=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODY1MzU1NiM1MTcyNTY2IzIwODI1NzU=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hepion-pharmaceuticals-to-participate-in-the-cantor-oncology-hematology-hemeonc-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Hepion Pharmaceuticals to Participate in the Cantor Oncology, Hematology &amp; HemeOnc Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Hepion Pharmaceuticals to Participate in the Cantor Oncology, Hematology &amp; HemeOnc Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/hepion-pharmaceuticals-to-participate-in-the-cantor-oncology-hematology-hemeonc-conference\/","og_locale":"en_US","og_type":"article","og_title":"Hepion Pharmaceuticals to Participate in the Cantor Oncology, Hematology &amp; HemeOnc Conference - Market Newsdesk","og_description":"EDISON, N.J., Sept. 26, 2022 (GLOBE NEWSWIRE) &#8212; Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (\u201cAI\u201d)-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis (\u201cNASH\u201d), hepatocellular carcinoma (\u201cHCC\u201d), and other chronic liver diseases, today announced that its Chief Medical Officer, Todd Hobbs, MD, will participate in the \u201cNovel Targets in Oncology: Risk vs. Reward\u201d panel at the Cantor Oncology, Hematology &amp; HemeOnc Conference on Wednesday, September 28, 2022 at 9:00 a.m. Eastern Time at the New York Palace Hotel. During the panel alongside other industry peers, Dr. Hobbs will focus his discussion on Hepion\u2019s upcoming Phase 2 clinical trial of rencofilstat in the treatment of HCC. Due to the format of the event, &hellip; Continue reading \"Hepion Pharmaceuticals to Participate in the Cantor Oncology, Hematology &amp; HemeOnc Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/hepion-pharmaceuticals-to-participate-in-the-cantor-oncology-hematology-hemeonc-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2022-09-26T21:04:31+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1MzU1NiM1MTcyNTY2IzIwODI1NzU=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hepion-pharmaceuticals-to-participate-in-the-cantor-oncology-hematology-hemeonc-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hepion-pharmaceuticals-to-participate-in-the-cantor-oncology-hematology-hemeonc-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Hepion Pharmaceuticals to Participate in the Cantor Oncology, Hematology &amp; HemeOnc Conference","datePublished":"2022-09-26T21:04:31+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hepion-pharmaceuticals-to-participate-in-the-cantor-oncology-hematology-hemeonc-conference\/"},"wordCount":381,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hepion-pharmaceuticals-to-participate-in-the-cantor-oncology-hematology-hemeonc-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1MzU1NiM1MTcyNTY2IzIwODI1NzU=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hepion-pharmaceuticals-to-participate-in-the-cantor-oncology-hematology-hemeonc-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/hepion-pharmaceuticals-to-participate-in-the-cantor-oncology-hematology-hemeonc-conference\/","name":"Hepion Pharmaceuticals to Participate in the Cantor Oncology, Hematology &amp; HemeOnc Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hepion-pharmaceuticals-to-participate-in-the-cantor-oncology-hematology-hemeonc-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hepion-pharmaceuticals-to-participate-in-the-cantor-oncology-hematology-hemeonc-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1MzU1NiM1MTcyNTY2IzIwODI1NzU=","datePublished":"2022-09-26T21:04:31+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hepion-pharmaceuticals-to-participate-in-the-cantor-oncology-hematology-hemeonc-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/hepion-pharmaceuticals-to-participate-in-the-cantor-oncology-hematology-hemeonc-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hepion-pharmaceuticals-to-participate-in-the-cantor-oncology-hematology-hemeonc-conference\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1MzU1NiM1MTcyNTY2IzIwODI1NzU=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1MzU1NiM1MTcyNTY2IzIwODI1NzU="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hepion-pharmaceuticals-to-participate-in-the-cantor-oncology-hematology-hemeonc-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Hepion Pharmaceuticals to Participate in the Cantor Oncology, Hematology &amp; HemeOnc Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/688988","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=688988"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/688988\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=688988"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=688988"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=688988"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}